<- Go Home
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Market Cap
$1.1B
Volume
914.1K
Cash and Equivalents
$350.7M
EBITDA
-$227.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$62.75
52 Week Low
$5.95
Dividend
N/A
Price / Book Value
3.42
Price / Earnings
-4.66
Price / Tangible Book Value
3.42
Enterprise Value
$804.5M
Enterprise Value / EBITDA
-3.57
Operating Income
-$229.2M
Return on Equity
54.33%
Return on Assets
-30.72
Cash and Short Term Investments
$380.5M
Debt
$75.7M
Equity
$291.2M
Revenue
N/A
Unlevered FCF
-$114.1M
Sector
Biotechnology
Category
N/A